Welcome to our dedicated page for LeonaBio news (Ticker: LONA), a resource for investors and traders seeking the latest updates and insights on LeonaBio stock.
LeonaBio, Inc. reports clinical-stage biopharmaceutical developments focused on novel therapeutics for diseases with high unmet medical needs. The company’s news centers on lasofoxifene, a selective estrogen receptor modulator being developed for treatment-resistant ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, along with broader pipeline work that includes small-molecule neurology candidates such as ATH-1105 and ATH-1020.
Recurring updates cover clinical and nonclinical data, oncology research presentations, key opinion leader events, financial results, licensing activity, private financing, board and executive changes, and the completed name and ticker transition from Athira Pharma to LeonaBio and LONA.
LeonaBio (LONA)/b) will participate in the Cantor Global Healthcare Conference 2026 in New York from September 9–11, 2026.Company management will join a fireside chat on Friday, September 11, 2026, from 9:45 am to 10:15 am EDT. A live webcast and at least 30-day replay will be available via the Investors section of LeonaBio’s website.
LeonaBio (NASDAQ:LONA) reported second quarter 2026 results and a business update, highlighting progress of its Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2‑negative, ESR1‑mutated metastatic breast cancer. The company has enrolled 495 patients and expects to complete ~600‑patient enrollment in 4Q 2026, with topline data anticipated in 2H 2027.
Lasofoxifene previously showed longer median progression‑free survival and higher objective response rates versus fulvestrant in Phase 2 ELAINE‑1, and meaningful activity in combination with abemaciclib in ELAINE‑2. Brelgometon (ATH‑1105) completed a Phase 1 trial in 80 healthy volunteers with a favorable safety and pharmacokinetic profile, supporting Phase 2 planning in ALS.
As of June 30, 2026, cash, cash equivalents and investments were $51.1 million, versus $88.3 million at year‑end 2025. Second‑quarter R&D expenses rose to $12.9 million and G&A to $6.6 million, driving a net loss of $19.0 million, or $0.80 per share.
LeonaBio (NASDAQ: LONA) reported that its lead candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology’s 4th Summit on Breast Cancer, held August 18-22, 2026, in Kona, Hawaii.
The company is on track to complete enrollment of the pivotal Phase 3 ELAINE-3 trial in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer in 4Q 2026, with topline data expected in 2H 2027. Presentations include an August 19 talk on ELAINE-3 and an August 20 industry lunch on lasofoxifene’s development and potential role in metastatic breast cancer treatment.
LeonaBio (NASDAQ:LONA) announced that Chief Medical Officer Javier San Martin, MD, presented on brelgometon (ATH-1105) at the 5th Annual ALS Drug Development Summit in Boston. The talk covered ALS trial strategy, biomarker integration, and adaptive methodologies.
Brelgometon is an oral, brain-penetrant positive modulator of the neurotrophic HGF system. According to LeonaBio, preclinical and Phase 1 data support advancing brelgometon into a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept, dose-ranging ALS study targeted to start in the second half of 2026.
LeonaBio (NASDAQ:LONA) will present at two June 2026 industry meetings. The company will give an oral presentation on ATH-1105 in ALS at the 5th Annual ALS Drug Development Summit and join an oncology trials panel at the BIO International Convention.
LeonaBio (NASDAQ: LONA) reported Q1 2026 results and pipeline updates. The company expects ELAINE-3 Phase 3 enrollment to complete in 4Q 2026 with topline data anticipated in 2H 2027. LeonaBio secured a $90M December 2025 financing with up to $146M additional warrant proceeds. Cash and investments were $67.7M at March 31, 2026; net loss was $32.9M for Q1 2026. The company plans a Phase 2 ALS study of ATH-1105 in 2H 2026 and reported supportive Phase 1 and nonclinical data for its programs.
LeonaBio (NASDAQ: LONA) appointed Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board effective May 5, 2026, and announced the retirement of long-serving director John Fluke Jr., effective May 4, 2026.
The new directors bring experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets to support LeonaBio's clinical pipeline advancement.
LeonaBio (NASDAQ: LONA) will host a virtual Key Opinion Leader event on April 29, 2026 at 12:00 p.m. ET to discuss lasofoxifene in treatment‑resistant ER+, HER2‑, ESR1‑mutated metastatic breast cancer. Management and two clinical experts will review the evolving treatment landscape.
The company expects to complete enrollment in ELAINE‑3 in 4Q26 with topline data anticipated in 2H27. The live webcast will be archived on LeonaBio's investor events page.
LeonaBio (NASDAQ: LONA) highlighted independent nonclinical data on lasofoxifene at AACR Annual Meeting 2026 showing bone-protective effects and sustained anti-tumor activity in ER+ and ESR1-mutant metastatic breast cancer animal models. The data support the scientific rationale for the ongoing ELAINE-3 Phase 3 study.
Researchers reported lasofoxifene reduced metastatic bone tumor burden while preserving bone microenvironment integrity in preclinical models.
LeonaBio (NASDAQ: LONA) reported full-year 2025 results and a business update after licensing lasofoxifene and closing a $90 million private placement, with warrants potentially providing up to an additional $146 million. Cash and investments were $88.3M at year-end 2025.
The company expects to complete enrollment of its Phase 3 ELAINE-3 trial in 4Q 2026 with topline data anticipated in 2H 2027, and to initiate a Phase 2 ALS study of ATH-1105 in 2H 2026.